Compare SKYT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYT | COLL |
|---|---|---|
| Founded | 1991 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2015 |
| Metric | SKYT | COLL |
|---|---|---|
| Price | $27.74 | $35.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $26.50 | ★ $50.83 |
| AVG Volume (30 Days) | ★ 872.7K | 397.6K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1842.86 | N/A |
| EPS | ★ 2.44 | 1.73 |
| Revenue | $442,139,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $40.53 | $6.07 |
| Revenue Next Year | $4.01 | N/A |
| P/E Ratio | ★ $10.74 | $20.59 |
| Revenue Growth | ★ 29.18 | 23.62 |
| 52 Week Low | $5.67 | $23.23 |
| 52 Week High | $36.07 | $50.79 |
| Indicator | SKYT | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 17.48 |
| Support Level | $14.54 | $34.30 |
| Resistance Level | $31.19 | $36.20 |
| Average True Range (ATR) | 1.06 | 1.61 |
| MACD | -0.23 | -0.74 |
| Stochastic Oscillator | 1.49 | 7.13 |
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.